Skip to main content

Revenues and Earnings Up for Qiagen in Q1

NEW YORK, May 4 (GenomeWeb News) - Qiagen yesterday reported increased revenues and slightly higher earnings for the first quarter of 2004.

 

The company booked $96.1 million in revenues, up from $79.6 million during the same quarter last year. Almost 80 percent of revenues resulted from consumables, and about 10 percent each from instruments and oligos.

 

Research and development costs climbed to $9.4 million, from $7.5 million during the same quarter in 2003.

 

Qiagen's net income increased slightly to $11.4 million, or $.08 per share, from $11 million, or $.08 per share, during the year-ago period.

 

As of March 31, Qiagen had $108.8 million in cash and cash equivalents.

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.